Dr. Yingying Cai is a science law clerk and registered patent agent in the firm’s Business Law department and a member of its Intellectual Property group. She joined Goodwin in 2020.
Dr. Cai assists clients with patent preparation, patent prosecution, patentability analysis, freedom-to-operate analysis, and intellectual property due diligence. She has experience in managing patent portfolios and developing domestic and foreign patent prosecution strategies. Prior to joining Goodwin, Dr. Cai was a patent agent at Pieris Pharmaceuticals, overseeing a global patent portfolio and advising IP-oriented business strategies.
Prior to joining Goodwin, Dr. Cai was a patent agent at Pieris Pharmaceuticals, where she managed a global patent portfolio in the areas of antibody mimetics, immuno-oncology, and respiratory diseases, oversaw day‑to-day prosecution matters, and supported IP-related executive decisions and business development activities.
Dr. Cai’s scientific research experience spans several laboratories and a broad range of disciplines, including chemistry, chemical biology, biochemistry, and structural biology. Dr. Cai conducted doctoral research focusing on structural-functional study and peptide-based drug design of G protein-coupled receptors. Dr. Cai is an author of research and review articles published in peer-reviewed journals including Chemical Communications, ACS Chemical Biology, Frontiers in Pharmacology, and PLOS ONE.
- U.S. Patent and Trademark Office (USPTO)